The pathologic evaluation of surgical specimens is the gold standard for diagnosing residual disease and pathologic complete response following neoadjuvant chemotherapy for breast cancer, but this approach can lead to over-treatment, according to Joerg Heil, MD.

Clinical practice guidelines are clear that sentinel lymph node biopsy (SLNB) is not warranted in most cases of ductal carcinoma in situ (DCIS).

Recurrence scores spare some patients from chemotherapy.